| Recruiting | A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With He NCT07416526 | Hoffmann-La Roche | Phase 3 |
| Not Yet Recruiting | Liver Biopsy Following Gene Therapy For Hemophilia NCT05932914 | St. Jude Children's Research Hospital | — |
| Recruiting | A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophili NCT07416604 | Hoffmann-La Roche | Phase 3 |
| Not Yet Recruiting | An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children NCT07088458 | Bayer | — |
| Recruiting | Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surg NCT05936580 | Octapharma | Phase 4 |
| Not Yet Recruiting | A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A NCT07226206 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Recruiting | SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis NCT04563520 | Emory University | Phase 3 |
| Recruiting | Joint Health, Balance and Quality of Life in Adults With Hemophilia A NCT07523399 | Yuzuncu Yil University | — |
| Not Yet Recruiting | Effects of Emicizumab Treatment in Patients With Hemophilia A NCT07190118 | Hasan Kalyoncu University | — |
| Recruiting | Long-term Anticoagulation in a Patient With Severe Hemophilia A NCT07314983 | University Hospital, Strasbourg, France | — |
| Not Yet Recruiting | Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients NCT06938659 | Dhaka Medical College | Phase 2 / Phase 3 |
| Recruiting | Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatme NCT06940830 | Swedish Orphan Biovitrum | Phase 4 |
| Recruiting | To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A NCT06833983 | Gritgen Therapeutics Co., Ltd. | Phase 3 |
| Withdrawn | Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B NCT06634836 | Pfizer | — |
| Recruiting | Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haem NCT06579144 | Swedish Orphan Biovitrum | Phase 1 |
| Recruiting | Manual Therapy in Hemophilic Arthropathy of the Ankle NCT06816056 | Investigación en Hemofilia y Fisioterapia | N/A |
| Not Yet Recruiting | Synovial Proliferation on Routine Ultrasound: Active or Inactive? NCT06809972 | Van Creveldkliniek | — |
| Terminated | Goal Attainment and Physical Activity in People With Hemophilia A NCT06530030 | Sanofi | — |
| Recruiting | A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A i NCT06684314 | Sanofi | — |
| Recruiting | Longitudinal Cohort of Thrombosis and Hemostasis Diseases NCT06727669 | Peking University People's Hospital | — |
| Unknown | Effect of Kinetic Chain Exercises on Muscle Strength, Joint Position Sense and Quality of Life in Children wit NCT06649175 | Cairo University | N/A |
| Recruiting | Measurement Properties in People with Hemophilia NCT06565481 | University of Zurich | N/A |
| Recruiting | Home Monitoring in Hemophilia a NCT06702579 | Radboud University Medical Center | — |
| Enrolling By Invitation | ATHNdataset Registry NCT06820515 | American Thrombosis and Hemostasis Network | — |
| Recruiting | Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A NCT04418414 | Expression Therapeutics, LLC | Phase 1 |
| Completed | Case and Use Scenario Study to Gain Knowledge on the User Needs for a Medical Device for Hemophilia a Monitori NCT06369740 | Enzyre B.V. | — |
| Completed | Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A NCT05248594 | Montefiore Medical Center | — |
| Recruiting | Hemophilia A Research Program NCT07414511 | University of Washington | — |
| Terminated | The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC C NCT06568302 | ApcinteX Ltd | Phase 3 |
| Suspended | Version Testing of EnzySystem Version A for Hemophilia A NCT06273865 | Radboud University Medical Center | — |
| Recruiting | A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (P NCT06349473 | Equilibra Bioscience LLC | Phase 1 |
| Unknown | A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia NCT06297655 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 |
| Enrolling By Invitation | Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII Prophylaxis NCT06816953 | Chulalongkorn University | N/A |
| Completed | EVALUATION of the OVERALL HAEMOSTATIC CAPACITY of MIM8 with GLOBAL HAEMOSTASIS ASSAYS and FIBRIN CLOT ULTRASTR NCT06212505 | Hospices Civils de Lyon | — |
| Completed | Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem NCT06357572 | Enzyre B.V. | — |
| Withdrawn | Study of a Gene Therapy Treatment for Hemophilia A NCT06297486 | Spark Therapeutics, Inc. | Phase 3 |
| Recruiting | A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously R NCT06145373 | Sanofi | Phase 4 |
| Completed | Effects of Ultrasound and Infrared on Joint Pain and Movement in Hemophilia A Patients. NCT07116993 | Danyal Ahmad | N/A |
| Recruiting | A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Pa NCT06222697 | Bayer | — |
| Recruiting | Safety and Efficacy Study of NGGT003 in Hemophilia A Patients NCT06238908 | Institute of Hematology & Blood Diseases Hospital, China | EARLY_Phase 1 |
| Recruiting | Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs NCT06111638 | Shanghai Xinzhi BioMed Co., Ltd. | Phase 2 / Phase 3 |
| Active Not Recruiting | Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A NCT06224907 | BioMarin Pharmaceutical | Phase 3 |
| Unknown | Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizum NCT06104826 | Newark Beth Israel Medical Center | — |
| Completed | Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises Patient With Hemoph NCT05879549 | Bahçeşehir University | N/A |
| Unknown | Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease NCT06014320 | Stanford University | — |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Pe NCT05987449 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Unknown | Patterns of Hemophilia Care in Assiut Children Patients NCT05980377 | Assiut University | — |
| Terminated | An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis Wit NCT05856266 | Swedish Orphan Biovitrum | Phase 4 |
| Recruiting | Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between NCT05022459 | Wayne State University | — |
| Unknown | Viscoelastic Properties of Lower Extremity Muscles in Patients With Hemophilia NCT05981313 | Hasan Kalyoncu University | — |
| Completed | Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects NCT06025552 | TiumBio Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A NCT06185335 | Biocad | Phase 1 / Phase 2 |
| Unknown | Impact of Emicizumab on Activated Clotting Time Using the i-STAT Alinity Analyzer NCT05856903 | University Hospital, Grenoble | — |
| Terminated | The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe He NCT05789524 | ApcinteX Ltd | Phase 2 |
| Active Not Recruiting | A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A NCT05911763 | Sanofi | — |
| Completed | A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A NCT05707351 | Takeda | Phase 3 |
| Terminated | A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus NCT05580692 | BioMarin Pharmaceutical | N/A |
| Terminated | A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real- NCT05395858 | Bayer | — |
| Completed | Satisfaction Regarding the Dispensing of Emicizumab (HEMLIBRA®) for Patients With Haemophilia A in France NCT05450640 | Hospices Civils de Lyon | — |
| Enrolling By Invitation | A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical NCT05768386 | BioMarin Pharmaceutical | — |
| Active Not Recruiting | An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Prob NCT05643560 | Bayer | — |
| Recruiting | Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophili NCT05568719 | Pfizer | Phase 3 |
| Unknown | Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting NCT05636163 | Qianfoshan Hospital | — |
| Recruiting | A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B NCT05611801 | Pfizer | Phase 3 |
| Terminated | Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5) NCT05605678 | ApcinteX Ltd | — |
| Unknown | Emotions in the Communication and Relationship Styles of Parents With Hemophilic Children. NCT05754619 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients. NCT05523128 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Completed | Baby Detect : Genomic Newborn Screening NCT05687474 | Centre Hospitalier Universitaire de Liege | — |
| Recruiting | ASC618 Gene Therapy in Hemophilia A Patients NCT04676048 | ASC Therapeutics | Phase 1 / Phase 2 |
| Completed | Factor IX as Adjunctive Therapy to Emicizumab (EMIX) NCT05281718 | Tulane University | EARLY_Phase 1 |
| Completed | Prophylaxis Regimen for Hemophilia A Patients NCT05036278 | Bayer | Phase 4 |
| Recruiting | A Study of FVIII Gene Therapy for Hemophilia A NCT05454774 | Institute of Hematology & Blood Diseases Hospital, China | EARLY_Phase 1 |
| Completed | Evaluation of the Training Program for Community Pharmacists for Dispensing Emicizumab (HEMLIBRA®) in France NCT05449197 | Hospices Civils de Lyon | — |
| Unknown | Validation and Reliability of the CHO-KLAT in Turkish NCT05439642 | Yuzuncu Yil University | N/A |
| Unknown | Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant NCT06158334 | Hospices Civils de Lyon | — |
| Unknown | Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia NCT05487976 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Unknown | UPLC-MS/MS Monitoring of Emicizumab Therapy NCT04472169 | University Hospital, Lille | — |
| Completed | Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A NCT05265767 | Christian Medical College, Vellore, India | Phase 1 |
| Completed | A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated NCT05147662 | Bayer | Phase 3 |
| Completed | Intensive Replacement Treatment in Haemophilia Patients With Synovitis NCT04784988 | Federico II University | Phase 4 |
| Withdrawn | Emicizumab PUPs and Nuwiq ITI Study NCT04030052 | Emory University | Phase 3 |
| Completed | A Study of ADVATE in People With Hemophilia A in India NCT04985682 | Baxalta now part of Shire | Phase 4 |
| Completed | A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatme NCT04876365 | Takeda | — |
| Unknown | Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells NCT04805021 | Nantes University Hospital | — |
| Recruiting | Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors NCT05145127 | Pfizer | Phase 3 |
| Unknown | Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy NCT05187936 | University Hospital, Montpellier | — |
| Completed | A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophil NCT04953000 | Takeda | — |
| Completed | Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctoco NCT05042440 | Sanofi | Phase 1 |
| Completed | Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast NCT05279924 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | N/A |
| Completed | A Study of TAK-660 in Surgical Procedures for People With Hemophilia A. NCT04941898 | Takeda | — |
| Completed | A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Pro NCT05251090 | Jiangsu Gensciences lnc. | Phase 1 |
| Completed | Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Dam NCT04091386 | Bayer | — |
| Completed | Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia NCT05804734 | Groupe Maladies hémorragiques de Bretagne | — |
| Active Not Recruiting | Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients Wi NCT04461639 | Bayer | — |
| Completed | Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST) NCT04731701 | Swedish Orphan Biovitrum | — |
| Completed | Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII NCT04845399 | Zhengzhou Gensciences Inc | Phase 3 |
| Withdrawn | POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapi NCT04690322 | University of Texas Southwestern Medical Center | Phase 4 |
| Completed | Health Related Quality of Life of Youth and Young Adults With Haemophilia A NCT04728217 | The League of Clinical Research, Russia | Phase 4 |
| Recruiting | Gene Therapy for Chinese Hemophilia A NCT04728841 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Active Not Recruiting | Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A NCT04644575 | Bioverativ, a Sanofi company | Phase 3 |
| Completed | Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A NCT04759131 | Bioverativ, a Sanofi company | Phase 3 |
| Unknown | Clinical and Health-related Outcome of rFVIIIFc Prophylaxis NCT04583930 | Prof. Dr. Dr. Thomas Hilberg | — |
| Withdrawn | Medication Adherence and Non-adherence in Adults With Rare Disease NCT04541875 | Xperiome | — |
| Completed | BT200 in Hereditary Bleeding Disorders NCT04677803 | Medical University of Vienna | Phase 2 |
| Completed | Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophi NCT04323098 | BioMarin Pharmaceutical | Phase 3 |
| Recruiting | National Longitudinal Cohort of Hematological Diseases NCT04645199 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Completed | An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusio NCT04456387 | Zhengzhou Gensciences Inc | Phase 3 |
| Terminated | Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A NCT04541628 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Chi NCT04565236 | Bayer | Phase 4 |
| Unknown | Preventing Inhibitor Recurrence Indefinitely NCT04621916 | Children's Hospital Los Angeles | Phase 4 |
| Unknown | Pulsed Electromagentic Field in Haemophilia NCT04590456 | Delta University for Science and Technology | N/A |
| Completed | A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patient NCT04560933 | BioMarin Pharmaceutical | — |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderat NCT04370054 | Pfizer | Phase 3 |
| Active Not Recruiting | A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A NCT04158934 | Baxalta now part of Shire | — |
| Unknown | Lentiviral FVIII Gene Therapy NCT03217032 | Shenzhen Geno-Immune Medical Institute | Phase 1 |
| Active Not Recruiting | Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A NCT03818763 | Medical College of Wisconsin | Phase 1 |
| Active Not Recruiting | A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health NCT04293523 | Swedish Orphan Biovitrum | — |
| Recruiting | Treatment of Hemophilia A Patients With FVIII Inhibitors NCT04023019 | Emory University | — |
| Completed | Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Mod NCT03938792 | Pfizer | Phase 3 |
| Completed | Gaining Insight Into the Complexity of Pain in Patients With Haemophilia NCT05606640 | Universiteit Antwerpen | — |
| Completed | A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants NCT04158648 | Hoffmann-La Roche | Phase 3 |
| Completed | Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A NCT04396639 | Pfizer | Phase 4 |
| Completed | Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint Examination NCT04133883 | Swedish Orphan Biovitrum | N/A |
| Completed | Physical Activity and FVIII Elimination: Relevance to Personalized Therapy in Severe Hemophilia A NCT05752565 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Unknown | PHYSICAL ACTIVITY AND FVIII CLEARANCE: RELEVANCE FOR PERSONALIZED THERAPY IN SEVERE HAEMOPHILIA A (PHYSEMO) NCT04303936 | Catholic University of the Sacred Heart | N/A |
| Unknown | Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Sever NCT03947320 | Sinocelltech Ltd. | Phase 3 |
| Active Not Recruiting | Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed Wi NCT03932201 | Bayer | — |
| Completed | Handheld Ultrasound (HHUS) for Home Use in Hemophilia NCT04131920 | Washington Institute for Coagulation | — |
| Completed | Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia NCT04072237 | Catalyst Biosciences | Phase 1 |
| Completed | Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post NCT04085458 | Bayer | Phase 4 |
| Withdrawn | Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis NCT02718677 | Pfizer | — |
| Unknown | Association Between Individual Clotting Factor Level Monitoring and the Risk of Bleeding Whilst Physical Activ NCT04845555 | Prof. Dr. Dr. Thomas Hilberg | — |
| Completed | The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a a NCT04073498 | ApcinteX Ltd | Phase 1 / Phase 2 |
| Completed | Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients Wi NCT04015492 | Bayer | Phase 1 |
| Unknown | Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients. NCT03947567 | Sinocelltech Ltd. | Phase 4 |
| Unknown | Personalized Medicine for Canadians With Hemophilia NCT03615053 | McMaster University | N/A |
| Unknown | Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. NCT04061109 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Unknown | Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. NCT04060836 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A NCT04131036 | Washington Institute for Coagulation | — |
| Unknown | A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for In NCT03747653 | Kaifeng Pharmaceutical (Group) Co., Ltd. | — |
| Completed | Post Marketing Surveillance Study for ADYNOVATE in South Korea NCT03824522 | Takeda | — |
| Completed | Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A NCT03815318 | Sinocelltech Ltd. | Phase 3 |
| Completed | Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy NCT03876301 | Spark Therapeutics, Inc. | — |
| Active Not Recruiting | Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 NCT03588299 | Bayer | Phase 1 / Phase 2 |
| Enrolling By Invitation | Early Check: Expanded Screening in Newborns NCT03655223 | RTI International | — |
| Completed | ATHN 8: Previously Untreated Patients (PUPs) Matter Study NCT03818529 | American Thrombosis and Hemostasis Network | — |
| Completed | Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With NCT03834727 | Oregon Health and Science University | — |
| Active Not Recruiting | Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A NCT03432520 | Spark Therapeutics, Inc. | — |
| Terminated | Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Ji NCT03603275 | Bayer | — |
| Completed | Exercise Versus DDAVP in Patients With Mild Hemophilia A NCT03379974 | Nationwide Children's Hospital | Phase 4 |
| Completed | A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adu NCT03587116 | Pfizer | Phase 3 |
| Terminated | Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq NCT03344003 | Octapharma | — |
| Terminated | Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor NCT03361137 | Genentech, Inc. | Phase 4 |
| Unknown | Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability NCT03533504 | McMaster University | — |
| Completed | Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A P NCT03315455 | Hoffmann-La Roche | Phase 3 |
| Terminated | Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 NCT03520712 | BioMarin Pharmaceutical | Phase 1 / Phase 2 |
| Completed | Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at NCT03392974 | BioMarin Pharmaceutical | Phase 3 |
| Completed | A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunte NCT03380780 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors NCT03417245 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | A Study of BAX 888 in Male Adults With Severe Hemophilia A NCT03370172 | Baxalta now part of Shire | Phase 1 / Phase 2 |
| Completed | Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies NCT03405337 | Bayer | — |
| Completed | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors NCT03417102 | Genzyme, a Sanofi Company | Phase 3 |
| Recruiting | World Bleeding Disorders Registry NCT03327779 | World Federation of Hemophilia | — |
| Completed | Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (B NCT03370913 | BioMarin Pharmaceutical | Phase 3 |
| Completed | BAY94-9027 PK Study Comparing to Another Long Acting Product NCT03364998 | Bayer | Phase 1 |
| Completed | A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhib NCT03191799 | Hoffmann-La Roche | Phase 3 |
| Terminated | Understanding Hemophilia A and B Drug Dosage Administration Patterns NCT03248141 | Pfizer | — |
| Completed | Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Fail NCT03103542 | Swedish Orphan Biovitrum | Phase 4 |
| Completed | A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulatio NCT03205163 | Bioverativ, a Sanofi company | Phase 1 / Phase 2 |
| Completed | A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophi NCT03061201 | Pfizer | Phase 2 |
| Completed | Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A NCT02971930 | Bayer | — |
| Active Not Recruiting | Gene Therapy for Haemophilia A. NCT03001830 | University College, London | Phase 1 / Phase 2 |
| Completed | Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia NCT03185897 | Baxalta now part of Shire | — |
| Terminated | INdividualized ITI Based on Fviii(ATE) Protection by VWF NCT03204539 | University of California, Davis | Phase 4 |
| Completed | Data Registry in Chinese Hemophilia A and B Patients NCT07101224 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Completed | Evaluation of a Standardized Protocol for Thrombin Generation Assay NCT03313531 | Lund University | — |
| Completed | ADYNOVATE Drug Use-Results Survey NCT03169972 | Takeda | — |
| Completed | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 W NCT03020160 | Hoffmann-La Roche | Phase 3 |
| Completed | A Gene Transfer Study for Hemophilia A NCT03003533 | Spark Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | German Pediatric Hemophilia Research Database NCT02912143 | Goethe University | — |
| Unknown | Comparison of Ideal vs. Actual Weight Base Factor Dosing NCT03286153 | Bloodworks | N/A |
| Terminated | BAX 802 in CHA With Inhibitors NCT02895945 | Baxalta now part of Shire | Phase 3 |
| Unknown | UK - EHL Outcomes Registry NCT02938156 | Royal Free Hospital NHS Foundation Trust | — |
| Completed | Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A NCT03915080 | Lund University | Phase 4 |
| Completed | Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor NCT02976753 | Swedish Orphan Biovitrum | — |
| Completed | Drug Use Investigation of Kovaltry in Hemophilia A Patients NCT02941783 | Bayer | — |
| Completed | Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT® NCT03006965 | Spanish Society of Thrombosis and Haemostasis | — |
| Unknown | Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A NCT02921945 | Sinocelltech Ltd. | Phase 3 |
| Completed | A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Withou NCT02847637 | Hoffmann-La Roche | Phase 3 |
| Terminated | The Hemophilia Ultrasound Project NCT02807753 | University of Miami | — |
| Unknown | Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A NCT02888223 | Sinocelltech Ltd. | Phase 1 |
| Completed | GAS-Hem Feasibility Study NCT02674997 | Baxalta now part of Shire | — |
| Unknown | Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients NCT02622646 | Hospital Universitario La Fe | — |
| Unknown | Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemop NCT02930317 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Completed | A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor NCT02795767 | Hoffmann-La Roche | Phase 3 |
| Withdrawn | Improved Factor VIII Inhibitor Evaluation NCT02726139 | Boston VA Research Institute, Inc. | — |
| Completed | Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs O NCT02581969 | Bayer | — |
| Completed | Virtual Reality for Hemophilia NCT03507582 | Nationwide Children's Hospital | N/A |
| Completed | Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study. NCT02851082 | University Hospital, Toulouse | N/A |
| Unknown | Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients Wi NCT02750085 | Victor Blanchette | — |
| Completed | BAX 826 Dose-Escalation Safety Study NCT02716194 | Baxalta now part of Shire | Phase 1 |
| Completed | Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Stud NCT02740413 | Pfizer | — |
| Completed | Ultrasonography in Hemophilic Joint Disease and Serum Markers NCT02634918 | Northwell Health | — |
| Completed | Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients i NCT02634723 | Baxalta now part of Shire | — |
| Completed | Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment NCT02396862 | Bayer | — |
| Terminated | PK Driven Prophylaxis for Hemophilia A NCT02634424 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | BAX 855 PK-guided Dosing NCT02585960 | Baxalta now part of Shire | Phase 3 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxi NCT02622321 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemop NCT02615691 | Baxalta now part of Shire | Phase 3 |
| Completed | A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or NCT02571569 | Bayer | Phase 1 |
| Completed | An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemop NCT02554773 | Genzyme, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A NCT02528968 | Hampshire Hospitals NHS Foundation Trust | N/A |
| Completed | Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers NCT02506023 | Emory University | Phase 1 |
| Terminated | Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes NCT02392156 | Bioverativ Therapeutics Inc. | — |
| Completed | Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A NCT02461992 | Pfizer | Phase 1 |
| Completed | Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and NCT02483208 | Bayer | Phase 1 |
| Completed | A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), a NCT02476942 | Hoffmann-La Roche | — |
| Completed | Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients NCT02727647 | Chulalongkorn University | Phase 4 |
| Completed | A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B NCT02418793 | OPKO Health, Inc. | Phase 1 |
| Completed | PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A NCT02492984 | Pfizer | Phase 4 |
| Completed | Platelet Function in Patients With Hemophilia A NCT02093065 | Boston Children's Hospital | — |
| Completed | Colorado Adult Joint Assessment Scale (CAJAS) Validation NCT02284789 | Bayer | N/A |
| Completed | 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece NCT02319070 | Bayer | — |
| Completed | An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc NCT02234323 | Bioverativ, a Sanofi company | Phase 3 |
| Completed | Web-based Application for the Population Pharmacokinetic Service - Phase 1 NCT02061072 | McMaster University | — |
| Unknown | Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Pat NCT02479087 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Phase 4 |
| Completed | Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ NCT02962765 | Octapharma | — |
| Unknown | Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe He NCT02282410 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Terminated | A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipun NCT02402829 | Children's Mercy Hospital Kansas City | — |
| Unknown | Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A NCT02280265 | Nanjing Medical University | N/A |
| Completed | BAX 855 Pediatric Study NCT02210091 | Baxalta now part of Shire | Phase 3 |
| Completed | An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A NCT02172950 | CSL Behring | Phase 3 |
| Completed | Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis NCT02263066 | Bayer | — |
| Completed | Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function NCT02225483 | CancerCare Manitoba | — |
| Completed | Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE NCT02190149 | Baxalta now part of Shire | — |
| Completed | China ADVATE PTP Study NCT02170402 | Baxalta now part of Shire | Phase 4 |
| Completed | Individualizing Hemophilia Prophylaxis Using Thromboelastography NCT02582060 | Children's Hospital Los Angeles | N/A |
| Completed | Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activatio NCT02911233 | University Hospital, Caen | — |
| Completed | Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A NCT01790828 | Pfizer | — |
| Completed | Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO NCT01959919 | Pfizer | — |
| Completed | A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients NCT02035605 | Sanofi | Phase 1 |
| Unknown | Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemop NCT02027779 | Green Cross Corporation | Phase 3 |
| Completed | Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures NCT01913405 | Baxalta now part of Shire | Phase 3 |
| Completed | BAX 855 Continuation NCT01945593 | Baxalta now part of Shire | Phase 3 |
| Completed | ADVATE 2 mL Post-Authorization Safety Surveillance (PASS) NCT02093741 | Baxalta now part of Shire | — |
| Completed | An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia NCT02199717 | The Hospital for Sick Children | — |
| Completed | Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A NCT01775618 | Bayer | Phase 3 |
| Unknown | Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A NCT01619046 | Green Cross Corporation | Phase 3 |
| Completed | Prophylaxis Versus on Demand Treatment for Children With Hemophilia A NCT01810666 | Bayer | Phase 4 |
| Completed | Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador NCT01589848 | Universidad del Azuay | — |
| Unknown | Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease NCT02061033 | Karolinska University Hospital | — |
| Completed | Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen NCT01757405 | Baxalta now part of Shire | Phase 3 |
| Completed | Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) NCT01736475 | Baxalta now part of Shire | Phase 2 / Phase 3 |
| Terminated | Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development NCT01445197 | CSL Behring | Phase 3 |
| Completed | Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A NCT02362581 | Chulalongkorn University | N/A |
| Completed | Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion NCT01458106 | Bioverativ Therapeutics Inc. | Phase 3 |
| Completed | Viscosupplementation in Patients With Hemophilic Arthropathy NCT01748201 | University of Sao Paulo General Hospital | Phase 4 |
| Completed | Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC) NCT01579903 | Pfizer | Phase 1 |
| Completed | Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222 NCT01653639 | Bayer | Phase 1 |
| Unknown | Personalized Prediction of Tolerance and Immunogenicity in Hemophilia NCT01626105 | Victor J Marder, M.D. | — |
| Completed | A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A NCT01580293 | Bayer | Phase 2 / Phase 3 |
| Completed | An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human NCT01486927 | CSL Behring | Phase 2 / Phase 3 |
| Withdrawn | Non Neutralizing Antibodies: Prevalence and Characterization NCT01541527 | University Hospital, Montpellier | — |
| Completed | Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously T NCT01454739 | Bioverativ Therapeutics Inc. | Phase 3 |
| Completed | Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult NCT01439971 | Catalyst Biosciences | Phase 1 |
| Completed | Inhibitor Development in Patients With Hemophilia A Undergoing Surgery NCT01571934 | Emory University | — |
| Completed | Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia NCT01477437 | The Hospital for Sick Children | N/A |
| Terminated | Osteoporosis and MRI Study in Hemophilia NCT01460147 | Baxalta now part of Shire | N/A |
| Terminated | Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A NCT01434511 | Baxalta now part of Shire | Phase 3 |
| Completed | BAX 855 Dose-Escalation Safety Study NCT01599819 | Baxalta now part of Shire | Phase 1 |
| Terminated | Early Prophylaxis Immunologic Challenge (EPIC) Study NCT01376700 | Baxalta now part of Shire | Phase 3 |
| Completed | Hemophilia Inhibitor Previously Untreated Patient Study NCT01652027 | The University of Texas Health Science Center, Houston | — |
| Completed | ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) NCT02078427 | Baxalta now part of Shire | — |
| Completed | Kogenate FS Regulatory Post-Marketing Surveillance NCT01386268 | Bayer | — |
| Completed | Socialization of Adult Men With Congenital Hemophilia A or B NCT01510418 | Dana-Farber Cancer Institute | — |
| Completed | A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patien NCT01233258 | Bayer | Phase 3 |
| Completed | Biomarkers Serum Collection Methodology Pilot Study NCT01318707 | Georgetown University | — |
| Completed | Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Adm NCT01184820 | Bayer | Phase 1 |
| Completed | Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World NCT01217255 | The Hospital for Sick Children | — |
| Completed | Study of Biostate® in Children With Hemophilia A NCT01229007 | CSL Behring | Phase 3 |
| Completed | Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII NCT00989196 | Octapharma | Phase 2 |
| Completed | Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia NCT01090206 | Virginia Commonwealth University | N/A |
| Completed | Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Set NCT00950170 | Pfizer | Phase 4 |
| Completed | Quality of Life Study of Helixate NexGen NCT01053715 | CSL Behring | — |
| Completed | Survey of Inhibitors in Plasma-Product Exposed Toddlers NCT01064284 | Fondazione Angelo Bianchi Bonomi | Phase 4 |
| Completed | Efficacy and Safety of IL-11 in DDAVP Unresponsive NCT00994929 | University of Pittsburgh | Phase 2 |
| Completed | Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A NCT01029340 | Bayer | Phase 3 |
| Completed | Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients NCT00914459 | Pfizer | Phase 4 |
| Terminated | Study of Ataluren (PTC124) in Hemophilia A and B NCT00947193 | PTC Therapeutics | Phase 2 |
| Completed | Health Related Quality of Life of Youth and Young Adults With Hemophilia A NCT01034904 | CSL Behring | — |
| Completed | Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America NCT00969319 | Bayer | — |
| Terminated | Individually Tailored Prophylaxis in Patients With Severe Hemophilia A NCT00995046 | Hospices Civils de Lyon | N/A |
| Completed | Study Evaluating Pharmacovigilance Of Refacto AF NCT00895037 | Pfizer | — |
| Completed | Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A NCT00916032 | Baxalta now part of Shire | Phase 4 |
| Completed | Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens NCT00927667 | Bayer | Phase 4 |
| Terminated | Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age NCT00759655 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Terminated | Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings NCT00884390 | Pfizer | Phase 4 |
| Unknown | Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia NCT00797381 | Shanghai Public Health Clinical Center | — |
| Completed | EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan NCT00932555 | Bayer | — |